Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.8
5.6
Journals
IJMS
Special Issues
New Insights of Biomarkers in Neurodegenerative Diseases
ijms-logo
Submit to Special Issue Submit Abstract to Special Issue Review for IJMS Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

New Insights of Biomarkers in Neurodegenerative Diseases

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Neurobiology".

Deadline for manuscript submissions: 10 July 2024 | Viewed by 3041

Special Issue Editor

Dr. Ioannis Liampas

E-Mail Website
Guest Editor
Department of Neurology, Faculty of Medicine, University of Thessaly, Volos, Greece
Interests: dementia; Alzheimer's disease; cognitive impairment; cognitive decline; neuropsychiatric manifestations
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Biomarkers are objectively measured biological indices of normal or pathogenic biological processes. They are associated with specific clinical endpoints: e.g., diagnostic biomarkers reflect the clinical state of an individual (whether a person has a particular disease or not), susceptibility biomarkers measure the risk of developing a disorder, prognostic biomarkers are used to determine disease progression, predictive biomarkers are utilized to identify potential responders to specific interventions, and so on. Occasionally, given their well-established clinical relevance, biomarkers are used as substitute endpoints, instead of clinical outcomes. Biological markers are considered to play an important role in clinical research and practice. In the context of neurogenerative disorders, they are necessary to improve the identification of individuals at high-risk of developing a condition and the diagnostic accuracy and categorization of patients. Currently, among neurodegenerative disorders, biomarkers specific for Alzheimer’s disease have been studied more rigorously. This collection aims to cover the most recent advances in the field of biomarkers for neurodegenerative disorders. Any types of manuscripts supported by the Journal—original research articles, brief reports, communications, narrative reviews, systematic reviews, and meta-analyses - pertaining to this topic are welcome. Potential topics include, but are not limited to: Imaging, CSF, blood and urine-based biomarkers; Clinical relevance of biomarkers; Potential use and limitations of current biomarkers; Biomarkers as surrogate endpoints; Biomarkers in drug development; Biological and clinical markers.

Dr. Ioannis Liampas
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  •  amyloid-β
  •  tau phosphorylated
  •  tau
  •  GFAP
  •  neurofilaments
  •  TDP-43
  •  progranulin
  •  a-synuclein
  •  magnetic resonance imaging
  •  positron emission tomography
  •  dopamine transporter scan

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

17 pages, 1947 KiB  
Article
Influence of Physiological Variables and Comorbidities on Plasma Aβ40, Aβ42, and p-tau181 Levels in Cognitively Unimpaired Individuals
by Francisco Martínez-Dubarbie, Armando Guerra-Ruiz, Sara López-García, Juan Irure-Ventura, Carmen Lage, Marta Fernández-Matarrubia, Ana Pozueta-Cantudo, María García-Martínez, Andrea Corrales-Pardo, María Bravo, Juan Martín-Arroyo, Jon Infante, Marcos López-Hoyos, María Teresa García-Unzueta, Pascual Sánchez-Juan and Eloy Rodríguez-Rodríguez
Int. J. Mol. Sci. 2024, 25(3), 1481; https://doi.org/10.3390/ijms25031481 - 25 Jan 2024
Cited by 1 | Viewed by 833
Abstract
Plasma biomarkers for Alzheimer’s disease (AD) are a promising tool that may help in early diagnosis. However, their levels may be influenced by physiological parameters and comorbidities that should be considered before they can be used at the population level. For this purpose, [...] Read more.
Plasma biomarkers for Alzheimer’s disease (AD) are a promising tool that may help in early diagnosis. However, their levels may be influenced by physiological parameters and comorbidities that should be considered before they can be used at the population level. For this purpose, we assessed the influences of different comorbidities on AD plasma markers in 208 cognitively unimpaired subjects. We analyzed both plasma and cerebrospinal fluid levels of Aβ40, Aβ42, and p-tau181 using the fully automated Lumipulse platform. The relationships between the different plasma markers and physiological variables were studied using linear regression models. The mean differences in plasma markers according to comorbidity groups were also studied. The glomerular filtration rate showed an influence on plasma Aβ40 and Aβ42 levels but not on the Aβ42/Aβ40 ratio. The amyloid ratio was significantly lower in diabetic and hypertensive subjects, and the mean p-tau181 levels were higher in hypertensive subjects. The glomerular filtration rate may have an inverse relationship on plasma Aβ40 and Aβ42 levels but not on the amyloid ratio, suggesting that the latter is a more stable marker to use in the general population. Cardiovascular risk factors might have a long-term effect on the amyloid ratio and plasma levels of p-tau181. Full article
(This article belongs to the Special Issue New Insights of Biomarkers in Neurodegenerative Diseases)
►▼ Show Figures

Figure 1

12 pages, 1292 KiB  
Article
Objective Physical Function in the Alzheimer’s Disease Continuum: Association with Cerebrospinal Fluid Biomarkers in the ALBION Study
by Stefanos N. Sampatakakis, Eirini Mamalaki, Eva Ntanasi, Faidra Kalligerou, Ioannis Liampas, Mary Yannakoulia, Antonios N. Gargalionis and Nikolaos Scarmeas
Int. J. Mol. Sci. 2023, 24(18), 14079; https://doi.org/10.3390/ijms241814079 - 14 Sep 2023
Viewed by 1761
Abstract
Cognitive and physical decline, both indicators of aging, seem to be associated with each other. The aim of the present study was to investigate whether physical function parameters (walking time and handgrip strength) are related to cerebrospinal fluid (CSF) biomarkers (amyloid-beta Aβ42 [...] Read more.
Cognitive and physical decline, both indicators of aging, seem to be associated with each other. The aim of the present study was to investigate whether physical function parameters (walking time and handgrip strength) are related to cerebrospinal fluid (CSF) biomarkers (amyloid-beta Aβ42, Tau, PhTau) in individuals in the Alzheimer’s disease (AD) continuum. The sample was drawn from the Aiginition Longitudinal Biomarker Investigation of Neurodegeneration study, comprising 163 individuals aged 40–75 years: 112 cognitively normal (CN) and 51 with mild cognitive impairment (MCI). Physical function parameters were measured at baseline, a lumbar puncture was performed the same day and CSF biomarkers were analyzed using automated methods. The association between walking time, handgrip strength and CSF biomarkers was evaluated by linear correlation, followed by multivariate linear regression models adjusted for age, sex, education and APOEe4 genotype. Walking time was inversely related to CSF Aβ42 (lower CSF values correspond to increased brain deposition) in all participants (p < 0.05). Subgroup analysis showed that this association was stronger in individuals with MCI and participants older than 60 years old, a result which remained statistically significant after adjustment for the aforementioned confounding factors. These findings may open new perspectives regarding the role of mobility in the AD continuum. Full article
(This article belongs to the Special Issue New Insights of Biomarkers in Neurodegenerative Diseases)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop